Open an account

Apyx Medical

APYX · NASDAQ

$2.44+$0.02 (+0.83%)TodayMarket closed ·
Prev close $2.42

About APYX

Apyx Medical Corp. operates as an energy-based medical technology company. The company is headquartered in Clearwater, Florida and currently employs 205 full-time employees. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. The company focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs.

Employees
205
Headquarters
Clearwater, Florida
Listed
Jul 22, 1983
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
apyxmedical.com

APYX key statistics

Market cap
102.78M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
156.18K
Volume
366.57K
Open price
$2.45
High today
$2.56
Low today
$2.42
52 Week high
$5.08
52 Week low
$2.34

Apyx Medical (APYX) at a glance

As of Oct 20, 2026, Apyx Medical (APYX) shares are priced at $2.44, giving the company a market cap of 102.78M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.42 and $2.56. The current price is 0.8% above the day's low and 4.7% below its high.

Volume so far is 366.57K shares, above the average of 156.18K shares a day.

Over the past year Apyx Medical has ranged from $2.34 to $5.08, and now sits 4% of the way up that range.

Apyx Medical met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported -$0.07 per share against an estimate of -$0.0836.

The average analyst price target is $6.63, 171.7% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $6.63
Low
$6.06
Now
$2.44
High
$8.40

APYX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 30.9% on average.

  1. Q3 FY24: reported -$0.14 per share against an estimate of -$0.1893
  2. Q4 FY24: reported -$0.12 per share against an estimate of -$0.1632
  3. Q1 FY25: reported -$0.10 per share against an estimate of -$0.1224
  4. Q2 FY25: reported -$0.09 per share against an estimate of -$0.0952
  5. Q3 FY25: reported -$0.05 per share against an estimate of -$0.1046
  6. Q4 FY25: reported -$0.03 per share against an estimate of -$0.0584
  7. Q1 FY26: reported -$0.05 per share against an estimate of -$0.1081
  8. Q2 FY26: reported -$0.07 per share against an estimate of -$0.0836

APYX news

  • Press releasePRNewswire

    Body by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway

  • Press releasePRNewswire

    Renuvion wins 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener"

  • A Preview Of Apyx Medical's Earnings

  • Earnings Scheduled For November 6, 2025

  • Press releasePRNewswire

    Renuvion® Brings Real Transformations to the Runway at Miami Swim Week

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Earnings Scheduled For May 8, 2025

Similar companies

Companies in the same industry as Apyx Medical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.